Table 2.
Lipid and other laboratory measurements during follow-up in JUPITER
| Baseline | 12 months | Change from baseline to 12 months | P* | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Women | Rosuvastatin | Placebo | Rosuvastatin | Placebo | Rosuvastatin | Placebo | |
| hsCRP, mg/L | 4.6 (3.1, 7.7) | 4.6 (3.1, 7.6) | 2.5 (1.4, 4.8) | 4.1 (2.4, 7.0) | −1.8 (−3.6, −0.6) | −0.6 (−2.2, 0.8) | <0.0001 |
| LDL cholesterol, mg/dL | 109 (97, 120) | 109 (95, 120) | 55 (44, 73) | 112 (97, 127) | −51 (−65, −27) | 4 (−7, 17) | <0.0001 |
| HDL cholesterol, mg/dL | 54 (46, 66) | 54 (46, 66) | 58 (48, 70) | 55 (46, 67) | 3 (−2, 8) | 1 (−4, 6) | <0.0001 |
| Triglycerides, mg/dL | 118 (88, 162) | 117 (88, 164) | 98 (76, 131) | 118 (89, 161) | −17 (−44, 3) | −1 (−23, 21) | <0.0001 |
| Total cholesterol, mg/dL | 192 (175, 205) | 192 (175, 205) | 138 (121, 163) | 196 (177, 215) | −51 (−68, −27) | 4 (−9, 19) | <0.0001 |
| Men | |||||||
| hsCRP, mg/L | 4.0 (2.7, 6.6) | 4.1 (2.7, 6.8) | 2.1 (1.2, 4.1) | 3.2 (1.8, 5.8) | −1.7 (−3.4, −0.4) | −0.8 (−2.5, 0.8) | <0.0001 |
| LDL cholesterol, mg/dL | 107 (92, 119) | 108 (92, 118) | 55 (44, 71) | 108 (92, 123) | −49 (−62, −29) | 3.0 (−9, 15) | <0.0001 |
| HDL cholesterol, mg/dL | 46 (38, 55) | 45 (38, 55) | 49 (41, 59) | 47 (39, 56) | 3 (−2, 8) | 1 (−3, 5) | <0.0001 |
| Triglycerides, mg/dL | 118 (83, 176) | 118 (84, 172) | 100 (73, 142) | 119 (86, 172) | −16 (−50, 7) | 2 (−26, 27) | <0.0001 |
| Total cholesterol, mg/dL | 182 (165, 196) | 182 (166, 195) | 129 (113, 151) | 185 (166, 203) | −50 (−66, −28) | 3 (−9, 17) | <0.0001 |
Values are median (25th,75th percentile).
*
P value comparing rosuvastatin versus placebo for the change from baseline to 12 months.